APA

Coiffier B., Osmanov E. A., Hong X., Scheliga A., Mayer J., Offner F., Rule S., Teixeira A., Walewski J., de Vos S., Crump M., Shpilberg O., Esseltine D., Zhu E., Enny C., Theocharous P., van de Velde H., Elsayed Y. A. & Zinzani P. L. (20111005). Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. : The Lancet. Oncology.

Chicago

Coiffier Bertrand, Osmanov Evgenii A, Hong Xiaonan, Scheliga Adriana, Mayer Jiri, Offner Fritz, Rule Simon, Teixeira Adriana, Walewski Jan, de Vos Sven, Crump Michael, Shpilberg Ofer, Esseltine Dixie-Lee, Zhu Eugene, Enny Christopher, Theocharous Panteli, van de Velde Helgi, Elsayed Yusri A and Zinzani Pier Luigi. 20111005. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. : The Lancet. Oncology.

Harvard

Coiffier B., Osmanov E. A., Hong X., Scheliga A., Mayer J., Offner F., Rule S., Teixeira A., Walewski J., de Vos S., Crump M., Shpilberg O., Esseltine D., Zhu E., Enny C., Theocharous P., van de Velde H., Elsayed Y. A. and Zinzani P. L. (20111005). Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. : The Lancet. Oncology.

MLA

Coiffier Bertrand, Osmanov Evgenii A, Hong Xiaonan, Scheliga Adriana, Mayer Jiri, Offner Fritz, Rule Simon, Teixeira Adriana, Walewski Jan, de Vos Sven, Crump Michael, Shpilberg Ofer, Esseltine Dixie-Lee, Zhu Eugene, Enny Christopher, Theocharous Panteli, van de Velde Helgi, Elsayed Yusri A and Zinzani Pier Luigi. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. : The Lancet. Oncology. 20111005.